Annovis Bio, Inc. SEC filings ANVS

Annovis Bio, Inc. has 314 filings in SEC EDGAR's recent list, going back to Jan 15, 2010. Its latest annual report, Form 10-K, was filed on Mar 13, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (material agreement, regulation fd disclosure). The company's fiscal year ends on December 31.

Annovis Bio, Inc. SEC filings
Form Description Filed Period
10-K Annual report Mar 13, 2026 Dec 31, 2025
ARS Annual report to shareholders May 1, 2025 Dec 31, 2024
10-K Annual report Mar 21, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 29, 2024 Dec 31, 2023
10-K Annual report Mar 29, 2024 Dec 31, 2023
ARS Annual report to shareholders Apr 28, 2023 Dec 31, 2022
10-K Annual report Mar 31, 2023 Dec 31, 2022
10-K Annual report Mar 2, 2022 Dec 31, 2021
10-K Annual report Mar 3, 2021 Dec 31, 2020
10-K Annual report Mar 25, 2020 Dec 31, 2019

Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ANVS (NYSE)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Malvern, PA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1477845
Former names
QR Pharma, Inc. (until Mar 15, 2019)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.